A class action brought against Hemispherx Biopharma by its shareholders has survived a motion to dismiss in federal court in Philadelphia.

Shareholders claimed securities fraud against the small Philadelphia-based pharmaceutical company after stock prices plummeted following the failure of the company’s flagship drug to get approval from the U.S. Food and Drug Administration.